icotinib   Click here for help

GtoPdb Ligand ID: 7641

Synonyms: BPI-2009H | Conmana®
Approved drug
icotinib is an approved drug (China (2011))
Compound class: Synthetic organic
Comment: Icotinib is a selective, orally available epidermal growth factor receptor tyrosine kinase inhibitor [1-3]. Icotinib is a 'pseudo' INN, that takes the form of an INN, but has not been submitted to the World Health Organisation for ratification.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 74.73
Molecular weight 391.15
XLogP 2.49
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C#Cc1cccc(c1)Nc1ncnc2c1cc1OCCOCCOCCOc1c2
Isomeric SMILES C#Cc1cccc(c1)Nc1ncnc2c1cc1OCCOCCOCCOc1c2
InChI InChI=1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25)
InChI Key QQLKULDARVNMAL-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Icotinib (as the hydrochloride salt, PubChem CID 44609731) is approved in China, to treat patients with non-small cell lung cancer (NSCLC). Click here to view icotinib trials registered with ClinicalTrials.gov.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Tumours carrying activating mutations of EGFR are significantly susceptible to treatment with EGFR tyrosine kinase inhibitors. The drug inhibits EGFR-driven pathways involved in cell differentiation, proliferation, angiogenesis, and apoptosis.